Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review

[1]  N. Chaput,et al.  Tumour burden and efficacy of immune-checkpoint inhibitors , 2021, Nature Reviews Clinical Oncology.

[2]  A. Chella,et al.  Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial , 2021, The Lancet.

[3]  S. Peters,et al.  SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Baolan Li,et al.  Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12). , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  Yunpeng Liu,et al.  Tislelizumab Plus Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (RATIONALE 304): A Randomized Phase 3 Trial. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  N. Yang,et al.  Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer , 2021, JAMA oncology.

[7]  N. Ajami,et al.  Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial , 2021, Nature Medicine.

[8]  G. Yancopoulos,et al.  Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial , 2021, The Lancet.

[9]  K. Goto,et al.  IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients , 2021, Cancer science.

[10]  D. Carbone,et al.  First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. , 2021, The Lancet. Oncology.

[11]  Ying Cheng,et al.  Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. , 2020, The Lancet. Respiratory medicine.

[12]  N. Reinmuth,et al.  Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. , 2020, The Lancet. Oncology.

[13]  G. Giaccone,et al.  Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. , 2020, The New England journal of medicine.

[14]  I. Wistuba,et al.  Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. , 2020, The Lancet. Oncology.

[15]  Ying Cheng,et al.  Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11). , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  A. Tafreshi,et al.  A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  Edward S. Kim,et al.  Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer , 2020, JAMA oncology.

[18]  R. Rosell,et al.  Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial. , 2020, JAMA oncology.

[19]  M. Socinski,et al.  Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  N. Reinmuth,et al.  ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  E. Felip,et al.  Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. , 2020, The Lancet. Oncology.

[22]  D. de Ruysscher,et al.  Combination of Immunotherapy and Radiotherapy-The Next Magic Step in the Management of Lung Cancer? , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  L. Thiberville,et al.  A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer , 2019, Scientific Reports.

[24]  Crispin J. Miller,et al.  Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse , 2019, Nature Medicine.

[25]  N. Reinmuth,et al.  Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[26]  M. Faehling,et al.  Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice , 2019, Oncology.

[27]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[28]  Ying Cheng,et al.  Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  M. Socinski,et al.  Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. , 2019, The Lancet. Respiratory medicine.

[30]  Charu Aggarwal,et al.  Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. , 2019, The Lancet. Respiratory medicine.

[31]  M. Satouchi,et al.  KEYNOTE‐025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1–positive advanced non–small‐cell lung cancer , 2019, Cancer science.

[32]  Y. Nishimura,et al.  Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer , 2019, AntiCancer Research.

[33]  Keunchil Park,et al.  Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. , 2018, The Lancet. Oncology.

[34]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[35]  Stephen Broderick,et al.  Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.

[36]  C. Faivre-Finn,et al.  Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[38]  D. Carbone,et al.  First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer , 2017 .

[39]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[40]  Walter J Curran,et al.  Lung cancer: current therapies and new targeted treatments , 2017, The Lancet.

[41]  L. Sequist,et al.  Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. , 2016, The Lancet. Oncology.

[42]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[43]  Keunchil Park,et al.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.

[44]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[45]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[46]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[47]  F. Cappuzzo,et al.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[48]  K. Mills,et al.  Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines , 2014, Oncogene.

[49]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[50]  B. Clausen,et al.  Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. , 2009, Cancer research.

[51]  Paula R Williamson,et al.  An overview of methods and empirical comparison of aggregate data and individual patient data results for investigating heterogeneity in meta-analysis of time-to-event outcomes. , 2005, Journal of Evaluation In Clinical Practice.

[52]  W. Schuette.  Treatment of brain metastases from lung cancer: chemotherapy. , 2004, Lung cancer.

[53]  G. Giaccone,et al.  Chemotherapy , 1929, Reactions Weekly.

[54]  B. Milleron,et al.  [IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer]. , 2018, Revue des maladies respiratoires.

[55]  S. Gettinger,et al.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. , 2017, The Lancet. Oncology.